Gilead Sciences | GILD - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
AbbVie USD -6.66B 3.39B 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Incyte USD 5.62B 455.37M 2026-03
J&J USD 81.19B 358M 2026-03
Merck USD 45.88B 6.73B 2026-03
Moderna USD 7.41B 1.24B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
United Therapeutics USD 5.9B 1.2B 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03